Innovation Council submission to the ITC investigation on the TRIPS Agreement
Innovation Council submitted these perspectives to the ITC investigation of COVID-19 Diagnostics and Therapeutics and Flexibilites under the TRIPS Agreement.
There are many actions that could help to improve the availability of COVID therapeutics and diagnostics; setting aside IP protection is not one of them. Based on experience, we expect this will not help in establishing further manufacturing capacity – and, in fact, weaker IP could make this likely to succeed. IP protection supports the extension of global biomanufacturing capacity, by making tech transfer more legally certain, and support innovation and commercialization of new solutions in this sector.